FDA-cleared profile

Second Opinion CC

Pearl Inc. · X-ray/Radiography · FDA-cleared (510(k))

Authorized purpose: Second Opinion CC assists dental health professionals as a second reader for caries on bitewing and periapical radiographs of permanent teeth in patients 19 years or older, displaying editable polygonal contours for clinician review; it does not replace a complete dentist review or clinical judgment.

Clinical role
Cloud-processed caries detection and localization as a second reader, with editable findings rendered in the client interface; final diagnosis and treatment decisions remain with the dentist.
Images and patients
X-ray/Radiography · Dental/Maxillofacial
Key limitation
Keep in mind: Exact K242522 labeling is limited to caries contouring on bitewing and periapical permanent-tooth radiographs for patients 19 years or older. It does not establish panoramic use or detection of the broader findings advertised for the current Second Opinion family. False positives and false negatives remain possible, and a complete dentist review is required.

Overview status: Source-reviewed overview

Report a correction
Clinical details Purpose, workflow fit, evidence, and safety record

Workflow navigation pilot

Workflow role has not yet been reviewed for this navigation pilot.

A tag identifies a documented role; it does not establish compatibility or local acceptance. Methods and sources

  • What does this software do?Authorized purpose: Second Opinion CC assists dental health professionals as a second reader for caries on bitewing and periapical radiographs of permanent teeth in patients 19 years or older, displaying editable polygonal contours for clinician review; it does not replace a complete dentist review or clinical judgment.
  • Which images or clinical context are in scope?Modality: X-ray/Radiography Anatomy or clinical context: Dental/Maxillofacial Input: Digital intraoral bitewing and periapical radiographs of permanent teeth in patients aged 19 years or older, sent through the application programming interface for cloud processing.
  • Who uses it?Intended users: Dental health professionals, including dentists, who review the radiograph, image findings, patient history, and in-vivo clinical assessment.
  • What does the software produce?Output: Machine-generated detection metadata rendered as editable polygonal overlays on the original radiograph to identify teeth and suspected carious lesions requiring clinical review.
  • What is its most important limitation?Key limitation: Exact K242522 labeling is limited to caries contouring on bitewing and periapical permanent-tooth radiographs for patients 19 years or older. It does not establish panoramic use or detection of the broader findings advertised for the current Second Opinion family. False positives and false negatives remain possible, and a complete dentist review is required.

Clinical takeaway. Clinical role: Second Opinion CC assists dental health professionals as a second reader for caries on bitewing and periapical radiographs of permanent teeth in patients 19 years or older, displaying editable polygonal contours for clinician review; it does not replace a complete dentist review or clinical judgment.

Evidence takeaway. Evidence from the reviewed source record: K242522's 500-image standalone comparison evaluates caries localization by polygon contours versus the predicate's bounding boxes. Endpoint definitions, image mix, lesion count, and false-positive burden are retained so the 90% sensitivity is not interpreted in isolation.

Evidence context

Evidence context not reviewed for this FDA record.

Public-label constraints

Label constraints have not been reviewed for this exact FDA record. Unknown is not all ages or evidence of unsuitability.

Public-label constraints, not patient-level eligibility or a medical recommendation. Training and evaluation populations are separate. Read the original labeling and confirm the exact release and protocol.

Purpose
Second Opinion CC assists dental health professionals as a second reader for caries on bitewing and periapical radiographs of permanent teeth in patients 19 years or older, displaying editable polygonal contours for clinician review; it does not replace a complete dentist review or clinical judgment.
  • Exact FDA submission
  • Checked 2026-09-08
Workflow role
Cloud-processed caries detection and localization as a second reader, with editable findings rendered in the client interface; final diagnosis and treatment decisions remain with the dentist.
  • Exact FDA submission
  • Checked 2026-09-08
Required input
Digital intraoral bitewing and periapical radiographs of permanent teeth in patients aged 19 years or older, sent through the application programming interface for cloud processing.
  • Exact FDA submission
  • Checked 2026-09-08
Output and clinician action
Machine-generated detection metadata rendered as editable polygonal overlays on the original radiograph to identify teeth and suspected carious lesions requiring clinical review.
  • Exact FDA submission
  • Checked 2026-09-08
Care setting
Dental practices reviewing eligible permanent-tooth bitewing and periapical radiographs for patients aged 19 years or older.
  • Exact FDA submission
  • Checked 2026-09-08
Intended users
Dental health professionals, including dentists, who review the radiograph, image findings, patient history, and in-vivo clinical assessment.
  • Exact FDA submission
  • Checked 2026-09-08
Limitations
Exact K242522 labeling is limited to caries contouring on bitewing and periapical permanent-tooth radiographs for patients 19 years or older. It does not establish panoramic use or detection of the broader findings advertised for the current Second Opinion family. False positives and false negatives remain possible, and a complete dentist review is required.
  • Exact FDA submission
  • Checked 2026-09-08
Evidence summary
K242522's 500-image standalone comparison evaluates caries localization by polygon contours versus the predicate's bounding boxes. Endpoint definitions, image mix, lesion count, and false-positive burden are retained so the 90% sensitivity is not interpreted in isolation.
  • Exact FDA submission
  • Checked 2026-09-08

Evidence

Performance evidence

Metrics are shown only when they are tied to a source, endpoint, population, and tested product version. Candidate literature without exact product and version linkage is not shown as product evidence.

Evidence summary
K242522's 500-image standalone comparison evaluates caries localization by polygon contours versus the predicate's bounding boxes. Endpoint definitions, image mix, lesion count, and false-positive burden are retained so the 90% sensitivity is not interpreted in isolation.
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-08
Reported sensitivity
Lesion-level sensitivity 90% (95% CI 87%-94%) at Jaccard index 0.4
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-08
Reported specificity
Research pending
  • Needs research
  • Exact FDA submission
  • Checked 2026-08-31

This field has not been curated yet.

Weighted alternative free-response ROC figure of merit

0.81 wAFROC FOM

  • EndpointCaries localization non-inferiority using polygonal contours at Jaccard index 0.4
  • Population500 dental radiographs: 249 periapical and 251 bitewing; 212 contained caries and 356 ground-truth lesions were marked
  • Tested versionSecond Opinion CC caries-contouring configuration described in K242522

Highest-rated ROC area under curve

0.88 HR-ROC AUC

  • EndpointSecondary caries-detection comparison against polygonal consensus ground truth
  • Population500 dental radiographs: 249 periapical and 251 bitewing
  • Tested versionSecond Opinion CC caries-contouring configuration described in K242522

Lesion-level sensitivity

90 percent

  • EndpointCaries lesion localization with overlap at or above Jaccard index 0.4
  • Population500 radiographs containing 356 ground-truth caries lesions across 212 abnormal images
  • Tested versionSecond Opinion CC caries-contouring configuration described in K242522

Average false positives per image

1.34 false positives per image

  • EndpointPredicted regions without ground-truth overlap at or above Jaccard index 0.4
  • Population500 dental radiographs
  • Tested versionSecond Opinion CC caries-contouring configuration described in K242522

K242522 Second Opinion CC standalone non-inferiority study

  • DesignStandalone non-inferiority comparison of polygonal Second Opinion CC with the bounding-box Second Opinion predicate using four-reader consensus ground truth and wAFROC as the primary efficacy paradigm.
  • Population500 images: 249 periapical and 251 bitewing; 212 caries-positive images with 356 lesions. The age metadata included 9 images from ages 12-18, 233 from ages 18-75, 13 from ages 75+, and 245 with unknown age despite labeling for patients 19 years or older.
  • Scopeexact submission
  • Tested versionSecond Opinion CC caries-contouring configuration described in K242522
  • Samplen=500
  • IndependenceSponsor or vendor study

K242522

Manufacturer-submitted regulatory evidence. The age-distribution mismatch and large unknown-age share should be addressed during local evidence review; the FDA summary does not provide a subgroup result for the labeled 19+ population.

Safety and lifecycle

Postmarket record

Recall and adverse-event records are shown only after product matching. Adverse-event reports do not establish incidence or causality.

Postmarket safety review
The exact-submission FDA recall query returned no native recall record for K242522. This limited query does not establish absence of recalls or other safety information.
  • Public source
  • Exact FDA submission
  • Checked 2026-09-08
Pricing & contracts Public price, contract terms, and reimbursement

Price not public here; enter your quote

Not publicly available: Reviewed sources do not publish an exact-product procurement price with a stated offer scope.

Reimbursement

No product-specific code

Pearl states in a patient-facing article that AI analysis is typically incorporated into routine dental diagnostic care and not billed separately; this is a vendor generalization, not an exact-product payer policy or coverage determination.

General dental insurance context stated by Pearl · United States

Do not infer reimbursement, patient cost, or contract pricing. Verify each payer, plan, underlying exam/X-ray benefit, provider agreement, and billing practice.

IT implementation Deployment, interfaces, data handling, and support

System and version relationships

Match the AI release, system build, configuration and region. Source documentation does not establish acceptance of an installed system.

No specific system/version pairing has completed review for this FDA record. A broad DICOM or product-family statement does not establish a named viewer build's support.

Review Merge, Visage, Sectra, AGFA and IntelePACS context

Integration chain: evidence at each hop

Public source context, not tested interoperability. Each hop needs its own release/configuration evidence. Missing or unavailable routes are not documented incompatibility. All local tests are planned, not passed; no installed-system acceptance is recorded.

Acquisition/source → routing → AI processing → returned objects → viewer/worklist/report → support owner

No specific route context has been source-reviewed for this record. Obtain both endpoint builds and documents; this is not a finding of incompatibility.

  1. Acquisition/source

    Source context, not route validation: Digital intraoral bitewing and periapical radiographs of permanent teeth in patients aged 19 years or older, sent through the application programming interface for cloud processing.

    Scope: Exact FDA submission.

    Confirm scanner/model, protocol, series completeness and both software builds.

    Field checked 2026-09-08 · FDA 510(k) K242522: Second Opinion CC

  2. Routing

    Source context, not route validation: The exact device contains an API, machine-learning modules, and a client interface: images and metadata pass through the API to cloud-based processing and detections return as metadata for interface rendering. Exact connectors and supported practice systems are not listed in the FDA summary.

    Scope: Exact FDA submission.

    Name gateways, destinations, transfer rules and failure visibility; a DICOM statement does not prove a route.

    Field checked 2026-09-08 · FDA 510(k) K242522: Second Opinion CC

  3. AI processing

    Source context, not route validation: Cloud-based processing with a Windows client environment, as described in the exact FDA substantial-equivalence comparison.

    Scope: Exact FDA submission. Current hosting region, tenancy, retention, service levels, and exact client requirements require vendor confirmation.

    Confirm processing location, queue ownership, exclusions and exact AI build.

    Field checked 2026-09-08 · FDA 510(k) K242522: Second Opinion CC

  4. Returned objects

    Source context, not route validation: Machine-generated detection metadata rendered as editable polygonal overlays on the original radiograph to identify teeth and suspected carious lesions requiring clinical review.

    Scope: Exact FDA submission.

    Confirm object classes, units, references and whether findings, overlays or measurements reach their intended destination.

    Field checked 2026-09-08 · FDA 510(k) K242522: Second Opinion CC

  5. Viewer/worklist/report

    Unresolved route: Machine-generated detection metadata rendered as editable polygonal overlays on the original radiograph to identify teeth and suspected carious lesions requiring clinical review.

    Scope: Exact FDA submission.

    Confirm the named viewer/worklist/report build, display behavior and report transfer. Output support alone does not establish this endpoint. The displayed source describes output, not validated end-to-end delivery.

    Field checked 2026-09-08 · FDA 510(k) K242522: Second Opinion CC

  6. Support owner

    Unresolved route: Not established for the exact route.

    Scope: Scope not established.

    Name the local, platform and AI supplier support owners and escalation path.

Planned local route tests

No tests below have been performed or accepted.

  1. Patient/study identity (planned). Use approved non-patient test data to verify identifiers, accession and result-to-study linkage at every hop.
  2. Study completeness (planned). Test missing views/series, partial transfer, late arrivals, priors and unsupported acquisition inputs; confirm explicit refusal or fallback.
  3. Ordering and duplicates (planned). Send out-of-order, repeated and corrected studies; verify worklist order, deduplication and no misleading stale results.
  4. Report transfer (planned). Verify output object types, annotations, units, report content, destination and availability of original images.
  5. Access (planned). Verify authorized roles, audit trail, denied access and support ownership at each destination.
  6. Latency and failures (planned). Agree a workload and turnaround target; test queues, timeouts, missing results and fallback reading.
  7. Updates and rollback (planned). Define version change control, revalidation triggers, stop-use criteria and a tested rollback route.

Local implementation checklist

Agree the evidence and acceptance owner with your team and suppliers. Checkmarks apply to this page only and are not acceptance receipts.

Open the printable evaluation checklist

Deployment
Cloud-based processing with a Windows client environment, as described in the exact FDA substantial-equivalence comparison.
  • Exact FDA submission
  • Checked 2026-09-08

Current hosting region, tenancy, retention, service levels, and exact client requirements require vendor confirmation.

Integration
The exact device contains an API, machine-learning modules, and a client interface: images and metadata pass through the API to cloud-based processing and detections return as metadata for interface rendering. Exact connectors and supported practice systems are not listed in the FDA summary.
  • Exact FDA submission
  • Checked 2026-09-08
Security
The exact FDA summary states that Pearl developed security controls and development/postmarket processes using the FDA's September 2023 premarket cybersecurity guidance and December 2016 postmarket cybersecurity guidance. It does not disclose the control scope, audit evidence, data flow, retention, or assurance period needed for procurement.
  • Exact FDA submission
  • Checked 2026-09-08
Monitoring
Monitor patient-age and image-type eligibility, upload and processing failures, result latency, contour edits, false positives per image, false-negative review, dentist/AI disagreement, downstream treatment acceptance, update control, complaints, cybersecurity events, and exact-submission recalls.
  • Exact FDA submission
  • Checked 2026-09-08

Buyer acceptance guidance derived from the exact workflow, risk description, and performance endpoints; it is not a claimed vendor monitoring service.

Exact API-to-client workflow

The exact submission describes an API that routes image data to cloud machine-learning modules and returns detection metadata to a Windows client for editable polygon rendering.

exact submission · checked 2026-09-08

Current Second Opinion family integrations

Pearl's current Second Opinion page describes native integrations with more than 40 imaging and practice-management systems plus a standalone web app, with vendor-led setup. This is family context and does not establish connector or feature availability for the exact K242522 configuration.

product family · checked 2026-09-08

Current family processing workflow

Pearl's current page says most current-family images load in under one minute and includes bitewing, periapical, and panoramic workflows across many findings. Only the exact K242522 caries, bitewing/periapical, permanent-teeth, and age-19+ scope is applicable to this dossier.

product family · checked 2026-09-08
Sources & review details FDA identity, research record, source ledger, and history

Regulatory identity

FDA record and catalog context

The FDA listing establishes the regulatory identity. It does not by itself establish local workflow fit, pricing, security, or performance in your environment.

FDA submission
K242522
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
Modality
X-ray/Radiography
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-08
Anatomy
Dental/Maxillofacial
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-08
Clearance type
510(k)
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
Decision date
2025-01-16
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
FDA status
FDA-cleared
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31

Research record

What has been checked

This audit distinguishes completed source review from fields that have not yet been researched.

Human reviewedStatus
2026-09-08Last searched
25Fields reviewed
12Source classes checked
0Screened PubMed leads
0Screened trial leads
0Unreviewed FDA recall leads

Stored PubMed and ClinicalTrials.gov candidate arrays were empty. No paper or trial was promoted; empty arrays do not establish absence of external evidence. The current discovery snapshot contains 0 PubMed and 0 ClinicalTrials.gov candidate records; its dated, count-matched human screening remains current. Unlinked candidates remain quarantined. Native FDA recall identifiers produced 0 postmarket candidate records; 0 have been reviewed (0 published, 0 rejected) and 0 remain unreviewed.

Candidate leads were screened against the exact product and tested version. Unlinked records remain quarantined.

Source classes: fda ai list, fda decision summary, acr ai central product, vendor product page, vendor patient education, fda device recall, literature index, trial registry, stored candidate metadata, pubmed, clinical trials, openfda device recall

Field review details

Recorded state, verification date, notes and sources for fields without a publishable value. Conflicting records stay explicitly unsettled here; no plain settled value is shown for them.

  • Public pricing: Not publicly available - checked 2026-09-08 - Exact FDA submission

    No public exact-product amount, pricing unit, term, minimum, implementation fee, or support inclusion was established.

  • Pricing model: Not yet reviewed
  • Setup and integration fees: Not yet reviewed
  • Recurring fees: Not yet reviewed
  • Minimum commitment: Not yet reviewed
  • Contract duration: Not yet reviewed
  • Renewal terms: Not yet reviewed
  • Cancellation terms: Not yet reviewed
  • Support and service terms: Not yet reviewed
  • Trial or pilot terms: Not yet reviewed
  • Reimbursement: Not publicly available - checked 2026-09-08 - Exact FDA submission

    Pearl's patient-facing blog says AI is typically not separately billed, but it is not payer policy and does not establish product reimbursement or underlying-service coverage.

  • Data hosting location: Not yet reviewed
  • Data retention: Not yet reviewed
  • Documented data use: Not yet reviewed
  • Hardware requirements: Not yet reviewed
  • Network requirements: Not yet reviewed
  • Identity and access: Not yet reviewed
  • Installation timeline: Not yet reviewed
  • Training: Not verified - checked 2026-09-08 - Exact FDA submission

    Role-based onboarding, clinical-use training, competency assessment, support terms, and retraining after updates were not established.

10 sources - 3 history items

Source ledger

  1. K242522 FDA decision source

    U.S. Food and Drug Administration - Accessed 2026-08-31

    Scope: regulatoryIdentity, purpose, modality, anatomy

  2. Artificial Intelligence-Enabled Medical Devices

    U.S. Food and Drug Administration - Accessed 2026-08-31

    Scope: regulatoryIdentity, modalityContext

  3. Second Opinion CC model card (K242522)

    American College of Radiology - Published 2026-08-17 - Accessed 2026-09-01

    Scope: purpose, modality, intendedUsers, careSetting, output, evidenceSummary, anatomy, evidenceStudies

  4. PubMed biomedical literature index

    U.S. National Library of Medicine - Accessed 2026-09-01

    Scope: evidenceDiscovery

  5. ClinicalTrials.gov study registry

    U.S. National Library of Medicine - Accessed 2026-09-01

    Scope: evidenceDiscovery, studyStatus

  6. openFDA Device Recall API

    U.S. Food and Drug Administration - Accessed 2026-09-02

    Scope: recallDiscovery, nativeSubmissionMatching

  7. FDA 510(k) K242522: Second Opinion CC

    U.S. Food and Drug Administration - Published 2025-01-16 - Accessed 2026-09-07

    Scope: identity, clinicalUse, modality, anatomy, workflow, evidence, implementation, security

  8. Second Opinion real-time dental pathology detection

    Pearl, Inc. - Accessed 2026-09-08

    Scope: productFamily, clinicalWorkflow, integrations, implementationCapabilities

  9. Dental check-up appointment with AI: cost and insurance considerations

    Pearl, Inc. - Published 2026-03-02 - Accessed 2026-09-08

    Scope: vendorEconomicsContext, patientFees, insuranceContext

  10. openFDA exact recall query for K242522

    U.S. Food and Drug Administration - Accessed 2026-09-07

    Scope: postmarketSafety

Research history

  1. K242522 FDA decision

    Regulatory record

    510(k)

  2. Source-review record updated

    Research record

    human reviewed

  3. Reader overview source-reviewed

    Editorial review

    Source-reviewed editorial overlay

Alternatives

Related tools to compare

FDA-cleared K251002

Videa Dental AI

VideaHealth Inc.

Authorized purpose: Analyzes bitewing, periapical, and panoramic intraoral radiographs from patients aged 3 years and older to identify and localize specified suspected dental findings, historical treatments, and normal anatomy; diagnostic use remains with trained dental professionals.

Modality
X-ray/Radiography
Anatomy
Dental/Maxillofacial
Decision
2025-09-19
FDA-approved P980025

LOGICON CARIES DETECTOR

CARESTREAM DENTAL LLC

Adjunct software evaluates digital intraoral radiographs for caries extending into dentin on unrestored proximal surfaces of secondary dentition.

Modality
X-ray/Radiography
Anatomy
Dental/Maxillofacial
Decision
1998-09-02
FDA-cleared K252086

DTX Studio Assist

Nobel Biocare C/O Medicim NV

Authorized purpose: Analyzes two-dimensional bitewing and periapical radiographs of permanent teeth in patients aged 15 and older to identify and localize caries, calculus, periapical radiolucency, root canal filling deficiency, discrepancy at an existing restoration margin, and bone loss; also supports alveolar bone-level measurement and restoration/dental-anatomy segmentation as an adjunct to dentist review.

Modality
X-ray/Radiography
Anatomy
Dental/Maxillofacial
Decision
2025-11-17
FDA-cleared K250264

SugarBug (1.x)

Bench7, Inc.

Authorized purpose: Provides automated concurrent-read detection and segmentation of caries on bitewing radiographs in patients 18 and older, adding information for the dentist while requiring complete dentist review and judgment.

Modality
X-ray/Radiography
Anatomy
Dental/Maxillofacial
Decision
2025-11-07

Correct this exact record

Copy this public context and add the field, proposed wording and original source before sending. Nothing here is submitted automatically. Form-specific prefill has not been verified.

Open existing correction destination

Permission to display a submission is not evidence verification. A submission enters editorial review; it does not approve a public change. Form availability, data entry, receipt, review and publication are separate steps. Data entry and receipt remain unverified.

Accepted repository change history

No entry has been added to this scoped change history for this record. This is not proof that the record never changed.

Correction policy and limits · Public repository change history